Mineral Content of Course Cereals Roughages as well as Their Requirement in Dairy Animals

The necessity of mineral for growth, reproduction and production as well as normal physiological functions of animal body is well documented. In most of the tropical countries coarse cereal stovers are second major feed resource after wheat and paddy straw used in the livestock feeding. The concentration of macro and trace minerals in crop residues depends on various factors including species (Singh et al., 2005). Further, limited information is available on coarse cereals stovers mineral content. Therefore, the present study was under taken to see the macro and micro mineral content of some coarse cereal stovers in relation to animal requirement

Mineral Content of Leguminous and Non-Leguminous Crop Residues \u3cem\u3evis a vis\u3c/em\u3e Their Requirement in Animals

The need of mineral for growth, reproduction and production as well as normal physiological functions of animal body is well recognized. In most of the tropical and sub-tropical countries crop residues constitute the major feed resource in the livestock. The concentration of macro and trace minerals in crop residues depend on various factors including genetic and species of plant viz., leguminous and non-leguminous (Singh et al., 1997). Further, limited information is available currently on different types of crop residues. Therefore, in the present study was under taken to see the macro and micro mineral status of some leguminous and non-leguminous crop residues in relation to animal requirement

Evaluation of boric acid as a mounting agent in a microbiology laboratory

Introduction: Boric acid is a low-toxicity, non-volatile mineral with is antiseptic, antifungal, and antiviral properties. It is used as a wettable powder, liquid (applied as a spray or aerosol), emulsifiable concentrate, granules, powders, dusts, pellets, tablets, paste, bait or crystalline rods, depending upon the circumstances and target. In light of this information, the present study is aimed to compare bacterial and fungal mounts with both lactophenol cotton blue (LCB) and Boric acid-methylene blue-glycerol (BMG) i.e., effectivity of boric acid as mounting agent since it is a disinfectant, antiseptic, preservative and suppresses conidiogenesis in fungi. Material and methods:This mounting agent of boric acid was compared with lactophenol cotton blue commercial solution. Results: BMG was found to be equally effective in comparison with LCB. Discussion: BMG can be a cheaper alternative to LCB for observing colonies from Saboraud’s dextrose agar

Buffalo Rearing System in Bhadawari Breeding Tract

Bhadawari buffalo is one of the recognized buffalo breeds in India, known for high milk fat content, which may go as high as 14% (Kushwaha et al., 2012). Zachariah (1941) had first described this breed as “Bhadawan” buffalo – the best breed of buffaloes in Uttar Pradesh and found in the districts of Agra and Etah (Central India). Presently Bhadawari Buffaloes are found in the ravines of Yamuna and Chambal rivers spread over in the states of Uttar Pradesh and Madhya Pradesh. These buffaloes have adapted to the harsh conditions of the ravines with undulating topography, thorny and scanty bushes, climatic stress and draught conditions. The buffaloes are of medium size with medium to low milk yield having high fat content. Animals are of copper color, have two white rings on the lower side of the neck and legs are comparatively shorter. Indiscriminate crossbreeding with Murrah buffaloes, for increasing milk production, during the last 3-4 decades has reduced the number of Bhadawari buffaloes in the region. Looking into the need to conserve this gene pool, Indian Council of Agricultural Research has initiated efforts on conservation and improvement of Bhadawari buffaloes at Indian Grassland and Fodder Research Institute, Jhansi (IGFRI) under Network program in the year 2001. The present study was conducted to collect the information regarding existing buffalo rearing practices adopted by the farmers in the Bhadawari breeding tract

Use of pea agar with Tween 80 for Dalmau technique for identification of Candida albicans

Introduction: Candida albicans produces devastating infections with considerable attributable mortality. Identification rests ofDalmau technique using rice extract agar, which is very prone to aerial contamination and drying and breakage. Materials andMethods: We here evaluated pea agar, with and without Tween 80, as medium for Dalmau technique for identifying C. albicansand compared it with rice extract agar. Results: Pea agar with Tween 80 was a very useful medium for identifying C. albicans.Conclusion: Pea agar with Tween 80 can be used for Dalmau technique for C. albicans identification

The International Natural Product Sciences Taskforce (INPST) and the power of Twitter networking exemplified through #INPST hashtag analysis

Background: The development of digital technologies and the evolution of open innovation approaches have enabled the creation of diverse virtual organizations and enterprises coordinating their activities primarily online. The open innovation platform titled "International Natural Product Sciences Taskforce" (INPST) was established in 2018, to bring together in collaborative environment individuals and organizations interested in natural product scientific research, and to empower their interactions by using digital communication tools. Methods: In this work, we present a general overview of INPST activities and showcase the specific use of Twitter as a powerful networking tool that was used to host a one-week "2021 INPST Twitter Networking Event" (spanning from 31st May 2021 to 6th June 2021) based on the application of the Twitter hashtag #INPST. Results and Conclusion: The use of this hashtag during the networking event period was analyzed with Symplur Signals (https://www.symplur.com/), revealing a total of 6,036 tweets, shared by 686 users, which generated a total of 65,004,773 impressions (views of the respective tweets). This networking event's achieved high visibility and participation rate showcases a convincing example of how this social media platform can be used as a highly effective tool to host virtual Twitter-based international biomedical research events

Critical success factor bagi program keusahawanan di jabatan perdagangan politeknik

Konsep Critical Success Factor berkait rapat mengenai pengurusan dalam mencapai misi dan matlamat perniagaan dalam sesebuah organisasi. Oleh itu, kajian ini adalah bertujuan untuk mengkaji empat elemen Critical Success Factor di Jabatan Perdagangan Politeknik seterusnya melihat kecenderungan pelajar untuk melibatkan diri dalam bidang keusahawanan. Kajian jenis kuantitatif ini telah dibuat ke atas pensyarah di Jabatan Perdagangan Politeknik bagi zon Utara. Seramai 190 sampel kajian yang terlibat dalam penyelidikan ini melalui pengedaran borang kaji selidik. Antara enam buah politeknik di zon Utara yang terlibat dalam penyelidikkan ini adalah Politeknik Politeknik Tunku Syed Sirajuddin, Perlis, Politeknik Sultan Abdul Halim Muazzam Shah, Kedah, Politeknik Tunku Sultanah Bahiyah, Kedah, Politeknik Seberang Perai, Pulau Pinang, Politeknik Ungku Omar, Perak dan Politeknik Sultan Azlan Shah, Perak. Data yang diperolehi dianalisis mendapati nilai skor min bagi ketiga-tiga persoalan kajian iaitu, mengenalpasti elemen Critical Success Factor yang digunakan, cabaran dalam usaha melaksanakan elemen Critical Success Factor dan mengenalpasti tahap kecenderungan pelajar untuk melibatkan diri dalam bidang keusahawanan adalah tinggi. Manakala bagi persoalan kajian keempat iaitu mencari hubungan korelasi Pearson antara elemen Critical Suceess Factor dengan kecenderungan pelajar untuk melibatkan diri dalam bidang keusahawanan adalah berada pada tahap lemah, sekaligus menunjukkan Ho tidak diterima. Kesimpulannya, elemen Critical Success Factor ini memainkan peranan dalam pembentukkan organisasi yang berkesan supaya pembentukan matlamat dan objektif tercapa

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview

Kinase inhibitor research is a comparatively recent branch of medicinal chemistry and pharmacology and the first small-molecule kinase inhibitor, imatinib, was approved for clinical use only 15 years ago. Since then, 33 more kinase inhibitor drugs have received regulatory approval for the treatment of a variety of cancers and the volume of reports on the discovery and development of kinase inhibitors has increased to an extent where it is now difficult—even for those working in the field—easily to keep an overview of the compounds that are being developed, as currently there are 231 such compounds, targeting 38 different protein and lipid kinases (not counting isoforms), in clinical use or under clinical investigation. The purpose of this review is thus to provide an overview of the biomedical rationales for the kinases being targeted on the one hand, and the design principles, as well as chemical, pharmacological, pharmaceutical, and toxicological kinase inhibitor properties, on the other hand. Two issues that are especially important in kinase inhibitor research, target selectivity and drug resistance, as well as the underlying structural concepts, are discussed in general terms and in the context of relevant kinases and their inhibitors